Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v17-EN Version v11-EN
Language English English
Date Updated 2023-09-27 2023-09-06
Drug Identification Number 00533688 00533688
Brand name TOBRAMYCIN FOR INJECTION TOBRAMYCIN FOR INJECTION
Common or Proper name TOBRAMYCIN FOR INJECTION TOBRAMYCIN FOR INJECTION
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients TOBRAMYCIN TOBRAMYCIN
Strength(s) 1.2G 1.2G
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 50 mL 50 mL
ATC code J01GB J01GB
ATC description AMINOGLYCOSIDE ANTIBACTERIALS AMINOGLYCOSIDE ANTIBACTERIALS
Reason for shortage Delay in shipping of the drug. Other (Please describe in comments)
Anticipated start date
Actual start date 2022-09-20 2022-09-20
Estimated end date 2023-09-27 2023-09-27
Actual end date 2023-09-26
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be extending the backorder on our Tobramycin for Injection, 1.2 g PBP Vial 50 mL until September 27, 2023. Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be extending the backorder on our Tobramycin for Injection, 1.2 g PBP Vial 50 mL until September 27, 2023.
Health Canada comments